Horizon CombinatoRx Contracts with Otsuka for Screening of Drug Candidates | GenomeWeb

NEW YORK (GenomeWeb) – Horizon Discovery today announced that its CombinatoRx division has entered into a contract with Otsuka Pharmaceutical Development and Commercialization to perform in vitro cell line screening of certain OPDC candidates in development.

Horizon CombinatoRx will receive $835,000 for the work, which is to be substantially completed by the end of the year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.